The HER2-enriched (HER2E) breast cancer intrinsic subtype is predictive of attaining pCR in patients treated with lapatinib, trastuzumab, or the combination added to neoadjuvant chemotherapy [6, 11–13]. The gene discussed is ERBB2; the disease is breast carcinoma.